論文

査読有り 国際誌
2018年9月

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

The oncologist
  • Maura L Gillison
  • ,
  • George Blumenschein Jr
  • ,
  • Jerome Fayette
  • ,
  • Joel Guigay
  • ,
  • A Dimitrios Colevas
  • ,
  • Lisa Licitra
  • ,
  • Kevin J Harrington
  • ,
  • Stefan Kasper
  • ,
  • Everett E Vokes
  • ,
  • Caroline Even
  • ,
  • Francis Worden
  • ,
  • Nabil F Saba
  • ,
  • Lara Carmen Iglesias Docampo
  • ,
  • Robert Haddad
  • ,
  • Tamara Rordorf
  • ,
  • Naomi Kiyota
  • ,
  • Makoto Tahara
  • ,
  • Manish Monga
  • ,
  • Mark Lynch
  • ,
  • Li Li
  • ,
  • Robert L Ferris

23
9
開始ページ
1079
終了ページ
1082
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1634/theoncologist.2017-0674

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

リンク情報
DOI
https://doi.org/10.1634/theoncologist.2017-0674
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29866947
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221824

エクスポート
BibTeX RIS